NCT01349660 - Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

December 31, 2016

Study Completion Date

December 29, 2018

Conditions

Glioblastoma Multiforme

Interventions

DRUG

Bevacizumab

Bevacizumab 10 mg/kg IV every 2 weeks

DRUG

BKM120

BKM120 orally (PO) once daily

Trial Locations (8)

Center for Cancer and Blood Disorders, Bethesda

Florida Hospital Cancer Institute, Orlando

Florida Cancer Specialists, St. Petersburg

Florida Cancer Specialists, Fort Myers

Tennessee Oncology, Nashville

Grand Rapids Oncology Program, Grand Rapids

Nebraska Methodist Hospital, Omaha

Yale School of Medicine, New Haven